Evaluation of therapeutic drug level monitoring of phenobarbital, phenytoin and carbamazepine in Iranian epileptic patients

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 2, 2007, Pages 121-125

  Babaei, A ^a   Eslamai, M H ^a  

^a YAZD UNIVERSITY   (Iran)

Author keywords

Carbamazepine; Phenobarbital; Phenytoin; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; EPILEPSY; FEMALE; FOCAL EPILEPSY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; STATISTICAL SIGNIFICANCE; TONIC CLONIC SEIZURE;

EID: 33847352626     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45121     Document Type: Article

References (19)

1. Aldenkamp AP, Alpherls WC, Moerland MC, Ottevanger N, Van Parys JA. Controlled-release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia. 1987; 28: 507-514.
2. Bareggi SR, Tata MR, Guizzaro A, Pirola R, Parisi Monza CG. Daily fluctuation of plasma levels with conventional and controlled-release carbamazepine: correlation with adverse effects. Int J Clin Psychopharmacol. 1994; 9: 9-16.
3. Bialer M, Levy RH, Perucca E. Does carbamazepine have a narrow therapeutic plasma concentration range? Ther Drug Monit. 1998; 20: 56-59.
4. Eichelbaum M, Bertilson L, Palmer L, Sjogvist F. Plasma levels of carbamazepine and carbamazepine 10,11-epoxide during treatment of epilepsy. Eur J Clin Pharmacol. 1976; 9: 417-421.
5. Ficker DM, Privitera M, Krauss G, Kanner A, Moore JL, Glauser T. Improved tolerability and efficacy in epilepsy patients with extended-release carbamazepine. Neurology. 2005; 65: 593-595.
6. Hanssen Y, Deleu D, Al Balushi K, Al Hashar A, AlZakwani I. Drug utilization pattern of antiepileptic drugs: a pharmacoepidemiologic study in Oman. J Clin Pharm Ther. 2002; 27: 357-364.
7. Hardman JG, Limbird LE. Goodman and Gilman's The Pharmacological Basis of Therapeutics (10th ed). London: McGraw-Hill; 2001. pp. 521-549.
8. Irshad YM, Hamdi AA, Al Homrani M. Evaluation of therapeutic drug monitoring of antiepileptic drugs. Int J Clin Pharmacol Ther. 2003; 41: 126-131.
9. Irving S. Methodology for analytical toxicology. Boca Raton, FL: CRC Press Vol 2; 1985. pp. 70-90.
10. Karande SC, Joshi MV, Kshirsagar NA, Shah PU. An analysis of epileptic patients non-responsive to drugs. J Assoc Phys India. 1992; 40: 7445-7447.
11. Karande SC, Dakvi SS, Kshirsagar NA. Shortcoming in the pharmacotherapy of epileptic children in Bombay, India. J Trop Pediatr. 1995; 41: 247-249.
12. Kozer E, Parvez S, Minassian BA, Kobayashi J, Veriee Z, Koren G. How high can we go with phenytoin? Ther Drug Monit. 2002; 24: 386-389.
13. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs. 2002; 16: 695-714.
14. Schumacher GE, Barr JT, Browne TR, Collins JF. Test performance characteristics of the serum phenytoin concentration (SPC): the relationship between SPC and patient response. The Veterans Administration Epilepsy Cooperative Study Group. Ther Drug Monit. 1991; 13: 318-324.
15. Snodgrass SR, Parks BR. Anticonvulsant blood levels: historical review with a pediatric focus. J Child Neurol. 2000; 15: 734-746.
16. Sperling MR. The consequences of uncontrolled epilepsy. CNS Specter. 2004; 9: 98-109.
17. Theodore WH. Rational use of antiepileptic drug levels. Pharmacol Ther. 1992; 54: 297-305.
18. Theodore WH, Narang PK, Holmes MD, Reves P. Carbamazepine level and its epoxide: relation of plasma levels to toxicity and clinical control. Ann Neurol. 1989; 25: 194-196.
19. Widdop B. Therapeutic drug level monitoring. London: Churchill-Livingstone; 1985. pp. 135-154.